Report a series of more than 2 billion varieties were exposed gold sales involving Zhengda Qing and so on

Text . . Linan's recent industry report letter has been exposed, a number of large varieties are alleged to be with gold sales, involving wake-up call, Conrad, Aroteni ... Wake up quiet, Conlet injection is accused of taking gold sales in the recent industry frequently surprised the report letter, September 8 evening, a drug agent province of the report letter flowed out, a pharmaceutical group in the market sales company, in the current national medical reform environment, to its agents and marketing staff, take away low-cost high-open and high rate, and instigated sales staff to medical institutions to promote the sale of gold, commercial bribery.
the drug involved in the report was mainly brain-wake, Conlet injections, mainly Chinese medicine injections.
meters of intranet data show that these two Chinese medicine injections have entered the 2019 Chinese public medical institutions terminal Chinese medicine products TOP20, wake-up injection last year sales of 2.864 billion yuan, Conlet injections last year sales of 2.355 billion yuan, are 2 billion single products.
is also worth noting that since the sixth edition of the new coronavirus pneumonia diagnosis and treatment program, chinese medicine injections such as sedative injections have been recommended for clinical use.
In recent years, various places have issued a list of key monitoring drugs, the above two drugs have also appeared in the local key monitoring drug catalog, for example, on November 7, 2019, Yonghe County People's Hospital in Linyi City, Shanxi Province, the first batch of national key monitoring of rational drug use drug catalog (chemicals and biological products), formed the "Shanxi Yonghe County Chinese Medicine Hospital first batch of key monitoring rational drug catalog (chemical and biological) Products), there are wake-up injections, July 12, 2019 Inner Mongolia released a national provincial key monitoring directory, involving a total of 38 varieties, which involves Conlet injections, September 2, 2019, Daqing Municipal People's Government issued a notice on the adjustment of the "Daqing City Key Monitoring Drug Catalog", a total of 74 varieties, including brain-settling injections, Kanglet injections ... Under strict control, if the above-mentioned sales of gold is true, the future of the state to crack down on pharmaceutical bribery will continue to increase.
Suspected of pharmaceutical bribery, Zhengda Tianqing was reported uniquely, September 7 also has a report letter circulating in the industry, the report letter detailed that "Linyi City People's Hospital Oncology Department used Zhengda Tianqing production of anti-tumor drug Alor hydrochloric acid There is an illegal sales behavior of tini capsules, atrotinie retail price of 3409 yuan a box, cancer patients a month treatment costs as high as 10227 yuan, which the hospital's oncology department, radiotherapy doctors each box to take 400 yuan rebate.
2019, a doctor in the oncology department has taken bribes of up to 200,000, and more than three doctors in the radiotherapy department have taken bribes of 100,000, according to the report.
at the same time oncologists pushed out patients out-of-hospital prescriptions, pharmacies for Linyi Guokang University pharmacy.
addition, magnesium glyphosate injection, injection with Esomeprazole, Biabenan, a rebate is 6 yuan, 8 yuan, 20 yuan.
, according to media reports, Linyi City People's Hospital is currently investigating and verifying the relevant information mentioned in the report letter.
hydrochloric acid atrotini capsules, which are at the forefront of the storm, are a new class of drugs developed by Zhengda Tianqing, and from 2018 to 2019, the drug has been approved for the treatment of advanced non-small cell lung cancer, soft tissue sarcoma, and third-line treatment of small cell lung cancer.
January 2020, the listing application for the 4th new adaptive disease of Zhengtian Qing hydrochloric acid atrotini capsule entered a new batch to be included in the priority review and approval list.
currently conducting 28 clinical trials involving nasopharyngeal cancer, esophageal squamous cancer, stomach cancer, thyroid cancer, and other tumors, according to the Insight database.
sales of the drug continued to rise as new adaptations continued to be approved.
2019, Andrrotini's sales in China's public medical institutions exceeded 2 billion yuan, becoming an anti-tumor drug TOP17 variety.
2020 China Biopharmaceutical Semi-Annual Report shows that core products such as Arodini drive rapid growth of the anti-tumor line.
4.02 billion yuan (-56.2%) of china's total revenue from anti-tumor products, accounting for 31.8% of revenue, and Androutini estimates that it contributed more than 2 billion yuan.
a new round of health care catalog adjustment is coming, the second half of the Year Alsotini is also expected to be through health care negotiations to incorporate new adaptations, the whole year is still expected to maintain rapid growth, and become China's biopharmaceutical anti-tumor line of the heaviest varieties.
industry speculated that Arondini would be the first domestically produced innovative drug with annual sales of more than $5 billion.
are the reports of medical bribery now? Just a few days ago, another report letter pointed out that some of the doctors in a hospital in Anhui Province and the medical representatives of Nanjing Zhengda Tianqing had an abnormal sales relationship, from which gold sales.
According to the report letter, "every box of drugs sold, enterprises to prescription doctors drug prices of about 12% of the cash, pharmaceutical representatives to doctors set tasks to achieve high monthly sales performance, in addition to the name of the meeting will give doctors lecture fees, in fact, is to sell more rebates..." It is worth noting that there are two similar content of the report letter outflow, but the name of the enterprise is different, involving Shandong Q Division and Jiangsu H Division.
the relevant reports, according to industry sources, hospital procurement staff are being investigated, there are pharmaceutical companies have been suspended.
And for the above-mentioned reporting behavior, Zheng Tianqing told the media that the company and product reputation has recently been vilified and vilified, the preliminary investigation is the malicious behavior of individual competitors, with the intention of confusing audio-visual to achieve the undet informable purposes, the company has started the relevant judicial proceedings, the use of legal means to safeguard the legitimate rights and interests of enterprises.
are not uncommon to report drug bribery, the recent reported phenomenon is frequent, @Research Pharmaceutical Daniel told Sina Pharmaceuticals, these are small play, may be caused by competition between enterprises.
In the past, gold sales practices were common in the industry, for example, before Zhengda Qing was exposed to bribery, a criminal judgment issued by the Jiangdu District People's Court in Yangzhou City, Jiangsu Province in 2017 showed that between December 2010 and January 2014, Zhengtian QingjiangDu District Sales Director Xu Shuanglong in Yangzhou City Jiangdu People's Hospital is responsible for the sale of the company's needle book (Bia Peinan), Gamma (magnesium licorice), gino (palono hydrochloride) and other drugs during the work, directly to Yangzhou City Jiangdu People's Hospital ICU, geriatrics, respiratory department and other department director and doctors bribed.
2019, the city of Xinyu, Jiangxi Province, cancelled the sale of some of its products due to the drug rebate incident.
, Jiangxi Province pharmaceutical procurement platform also issued a notice to cancel Lianyungang Zhengtianqing Pharmaceutical Co., Ltd. the province's drug online qualification, for a period of two years.
recent years, medical reform into the deep water area, crack down on medical bribery has become a top priority.
this year, state regulators have frequently issued anti-corruption documents on the field of pharmaceutical purchase and sale.
For example, in June this year, nine ministries joined forces to crack down on pharmaceutical enterprises and CSO collusion, pharmaceutical representatives for the record management measures to consult again, the State Health Insurance Administration set up a pharmaceutical prices and credit evaluation system, multi-sectoral joint efforts to combat illegal practices in the field of pharmaceutical purchase and sale, from July until the end of the year, the National Health and Safety Commission will focus on the treatment of medical personnel to collect rebates, drug companies illegal marketing and other acts.
with the volume of procurement and other promotion, with gold sales and other models will be completely cool, pharmaceutical compliance has become a survival fundamental.
medical environment is being cleaned up period, at this time the top wind perpetrators, the consequences can be imagined.
note: The report letter in this article comes from the Internet